Abstract
The most comprehensive review to date of medicinal cannabinoids for the treatment of mental disorders has concluded that the evidence is insufficient to justify their use. A greater number of high‐quality trials is necessary to assess the safety and efficacy of medical cannabis and derivatives such as the increasingly popular cannabidiol (CBD), authors of the review and meta‐analysis stated. Results were published online Oct. 28 in Lancet Psychiatry.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
